Aeluma, Inc. filings document the reporting record of a Nasdaq-listed emerging growth semiconductor company developing scalable photonic and electronic technologies. Its periodic and current reports cover financial results, quarterly reporting, Regulation FD materials, investor presentations and public-company disclosure controls.
The company’s SEC filings also describe capital-structure activity involving common stock, shelf registration, underwriting agreements and sales-agreement arrangements for registered equity issuance. Governance disclosures include annual meeting voting results, director elections and shareholder approvals, while other current reports address material definitive agreements and Rule 10b5-1 trading-plan disclosures.
Aeluma, Inc. (ALMU) director Steven Denbaars reported amended insider sales of common stock. He sold 12,500 shares on 2026-08-26 at a weighted average price of $13.8435 per share and another 12,500 shares on 2026-08-27 at a weighted average price of $13.8158 per share. Both transactions were effected under a Rule 10b5-1 trading plan adopted on November 20, 2025. The amendment states it was filed solely to include previously omitted details of this trading plan.
Aeluma, Inc. (ALMU) director Steven Denbaars reported two open-market sales of common stock. He sold 12,500 shares on August 26, 2026 at a weighted average price of $13.8435 per share and 12,500 shares on August 27, 2026 at a weighted average price of $13.8158, in multiple trades within the disclosed price ranges.
Aeluma, Inc. (ALMU) received a notice under Rule 144 that director Steven DenBaars plans to sell 25,000 shares of Aeluma common stock through broker Merrill Lynch. The shares were acquired on February 5, 2021 via an Incentive Stock Option exercised for cash and are being sold pursuant to a Rule 10b5-1 trading plan. The notice lists an approximate sale date of August 26, 2026 and reports 18,305,335 shares of common stock outstanding.
Aeluma, Inc. director and Chief Executive Officer Jonathan Klamkin reported several transactions in common stock on August 3, 2026. He recorded bona fide gifts totaling 40,000 shares, including a 20,000-share disposition of shares held indirectly through a family trust and a 20,000-share acquisition into direct ownership. He also sold 20,000 shares in open-market or private transactions under a Rule 10b5-1 trading plan adopted on December 3, 2025, consisting of 4,190 shares at a weighted-average price of $16.2918 per share (range $15.62–$16.61) and 15,810 shares at $16.8487 per share (range $16.62–$17.53).
Aeluma, Inc. entered a CHIPS and Science Act Letter of Intent with the U.S. Department of Commerce’s CHIPS Research & Development Office for up to $30 million in proposed funding. The LOI supports R&D and commercialization of Aeluma’s scalable non-InP photonics manufacturing platform for AI and advanced computing applications.
The potential award is subject to further due diligence, required U.S. government approvals, and execution of definitive award documents. The LOI contemplates a portion of funds paid up front and the balance on a milestone-based structure, with Aeluma issuing unregistered equity securities to Commerce with an aggregate value equal to any final award.
BlackRock, Inc. reported a passive ownership stake in AELUMA INC common stock. BlackRock beneficially owns 963,791 shares of Aeluma common stock, representing 5.3% of the outstanding class as of the reporting date.
BlackRock has sole voting power951,382 shares and sole dispositive power963,791 shares, with no shared voting or dispositive power. Various underlying clients and investors have rights to dividends or sale proceeds, but no single underlying holder has more than 5% of Aeluma’s outstanding common shares.
Aeluma, Inc. reports that CEO Jonathan Klamkin executed multiple common stock transactions on July 1, 2026. One bona fide gift disposition moved 20,000 shares held indirectly by a family trust, and a separate gift transaction recorded acquisition of 20,000 shares into his direct ownership.
He then sold 19,900 shares at a weighted average price of $21.081 per share in transactions priced between $20.54 and $21.52, plus an additional 100 shares at $21.56, in open market or private transactions. After these trades, he holds 2,403 shares of Aeluma common stock directly. Footnotes explain that the sales were effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2025.
Morgan Stanley Smith Barney LLC submitted a Form 144 disclosing proposed resale of 40,000 shares of Common Stock identified as Founders Shares with an original issuance date of 10/27/2020. The excerpt lists two 10b5-1 sales by Jonathan Klamkin: 20,000 shares sold on 06/01/2026 for $500,662 and 20,000 shares sold on 05/01/2026 for $499,242.
Aeluma, Inc. Chief Executive Officer Jonathan Klamkin reported multiple insider transactions in the company’s common stock. On June 1, 2026, he sold a total of 20,000 shares in open-market transactions under a pre-arranged Rule 10b5-1 trading plan adopted on December 3, 2025.
The sales were executed in several tranches at weighted average prices of $22.19, $23.32, $24.39, $25.12 and $26.25 per share. He also made bona fide gifts totaling 40,000 shares, including 20,000 shares from his direct holdings and 20,000 shares from an indirect position held by a family trust.
Following these transactions, Klamkin directly holds 22,403 shares of Aeluma common stock and indirectly holds 1,366,995 shares through a family trust.
Aeluma, Inc. director Steven Denbaars reported open-market sales of 25,000 shares of Common Stock. The sales occurred on May 19–20, 2026 at weighted average prices ranging from about $19.56 to $21.30 per share, executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 20, 2025. Following these transactions, he directly holds 370,209 shares of Aeluma common stock.